Grade 3 and 4 toxicities, dose reductions, and drug discontinuations in each treatment arm
| . | RD . | IRD . | P value . |
|---|---|---|---|
| n = 161 . | n = 171 . | ||
| Toxicity | |||
| Hematological | |||
| Neutropenia | 64 (39.7%) | 64 (37.4%) | NS |
| Thrombocytopenia | 12 (7.4%) | 28 (16.3%) | .011 |
| Nonhematological | |||
| Infections | 34 (21%) | 49 (28%) | NS |
| Skin | 3 (1.8%) | 7 (4%) | NS |
| Gastrointestinal | 4 (2.4%) | 27 (15.7%) | < .0001 |
| Fatigue | 11 (6.8%) | 11 (6.4%) | NS |
| Deep vein thrombosis | 3 (1.8%) | 5 (2.9%) | NS |
| Dose reductions | |||
| Ixazomib | - | 50 (29.2%) | - |
| Lenalidomide | 33 (20.4%) | 50 (29.2%) | .06 |
| Dexamethasone | 38 (23.6%) | 35 (20.4%) | NS |
| Drug discontinuations | |||
| Ixazomib | - | 18 (10.5%) | - |
| Lenalidomide | 2 (1.2%) | 2 (1.1%) | NS |
| Dexamethasone | 14 (8.6%) | 8 (4.6%) | NS |
| . | RD . | IRD . | P value . |
|---|---|---|---|
| n = 161 . | n = 171 . | ||
| Toxicity | |||
| Hematological | |||
| Neutropenia | 64 (39.7%) | 64 (37.4%) | NS |
| Thrombocytopenia | 12 (7.4%) | 28 (16.3%) | .011 |
| Nonhematological | |||
| Infections | 34 (21%) | 49 (28%) | NS |
| Skin | 3 (1.8%) | 7 (4%) | NS |
| Gastrointestinal | 4 (2.4%) | 27 (15.7%) | < .0001 |
| Fatigue | 11 (6.8%) | 11 (6.4%) | NS |
| Deep vein thrombosis | 3 (1.8%) | 5 (2.9%) | NS |
| Dose reductions | |||
| Ixazomib | - | 50 (29.2%) | - |
| Lenalidomide | 33 (20.4%) | 50 (29.2%) | .06 |
| Dexamethasone | 38 (23.6%) | 35 (20.4%) | NS |
| Drug discontinuations | |||
| Ixazomib | - | 18 (10.5%) | - |
| Lenalidomide | 2 (1.2%) | 2 (1.1%) | NS |
| Dexamethasone | 14 (8.6%) | 8 (4.6%) | NS |
NS, not significant.